Diabetes Research Center, Dokter van Deenweg 1, 8025 BP Zwolle, the Netherlands; Epidemiology Unit, Department Innovation and Science, Isala Hospital, Dokter van Deenweg 1, 8025 BP Zwolle, the Netherlands.
Diabetes Research Center, Dokter van Deenweg 1, 8025 BP Zwolle, the Netherlands; Department of Endocrinology, University of Groningen and University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands.
Diabetes Res Clin Pract. 2023 Jun;200:110719. doi: 10.1016/j.diabres.2023.110719. Epub 2023 May 19.
To explore determinants of excessive weight gain after initiation of insulin therapy in type 2 diabetes mellitus (T2DM), in particular variables identified in the pre-insulin phase.
We performed a retrospective observational intervention cohort study, by means of a new user design/ inception cohort concerning n = 5086 patients. We studied determinants of excessive weight gain (5 kg or more) in the first year after initiation of insulin therapy, using both visualization and logistic regression analysis with subsequent receiver operation characteristic (ROC) analyses. Potential determinants pre-, at- and post-insulin initiation were included.
One out of 10 patients (10.0%) gained 5 kg weight or more. The earliest determinants of excessive weight gain were weight change (inversely) and HbA1c change in the two years prior to insulin therapy (p < 0.001). Patients that lost weight parallel with HbA1c rise in the two-years pre-insulin, showed the most pronounced weight gain. Of these patients, roughly one out of five (20.3%) gained 5 kg weight or more.
Clinicians and patients should be alert for excessive weight gain after initiation of insulin, in the case of weight loss prior to insulin therapy initiation, particularly with increasing and prolonged high HbA1c at (and after) insulin initiation.
探讨 2 型糖尿病(T2DM)患者起始胰岛素治疗后体重过度增加的决定因素,特别是在胰岛素前阶段确定的变量。
我们通过新用户设计/起始队列进行了一项回顾性观察性干预队列研究,涉及 n=5086 例患者。我们使用可视化和逻辑回归分析,随后进行接收者操作特征(ROC)分析,研究了胰岛素治疗起始后第一年体重过度增加(增加 5 公斤或更多)的决定因素。纳入了起始胰岛素前、胰岛素起始时和起始后潜在的决定因素。
每 10 名患者中就有 1 名(10.0%)体重增加 5 公斤或更多。体重变化(反方向)和胰岛素治疗前两年的 HbA1c 变化是体重过度增加的最早决定因素(p<0.001)。在胰岛素前两年体重下降与 HbA1c 升高平行的患者,体重增加最为明显。其中,大约五分之一(20.3%)的患者体重增加了 5 公斤或更多。
在开始胰岛素治疗的情况下,如果在开始胰岛素治疗前体重减轻,特别是在开始胰岛素治疗时(和之后)HbA1c 升高且持续时间长,临床医生和患者都应该警惕胰岛素治疗后体重过度增加。